Minimed Group Analyst Price Targets

Wall Street analyst price targets and consensus rating for Minimed Group (MMED).

Price Target Range — 3 Quarters

Analyst Consensus — 12 Analysts

11Buy

1Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$25Upside to Avg. PT+7.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 3, 2026	Morgan Stanley	Kallum Titchmarsh	PT Raise	Overweight	$19→$21
Sep 2, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$23→$26
Sep 2, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$20→$27
Sep 2, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$22→$26
Sep 2, 2026	UBS	Patrick Wood	PT Raise	Buy	$25→$28
Sep 2, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$21→$26
Sep 2, 2026	B of A Securities	Travis Steed	PT Raise	Buy	$24→$28
Sep 1, 2026	BTIG	Marie Thibault	PT Raise	Buy	$25→$28
Jul 28, 2026	UBS	—	Assumes	Buy	$25
Jun 4, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Overweight	$26→$22
May 18, 2026	B of A Securities	Travis Steed	PT Cut	Buy	$27→$20
May 12, 2026	Benchmark	Bruce Jackson	Initiate	Buy	$20
Apr 1, 2026	Barclays	Matt Miksic	Initiate	Overweight	$26
Mar 31, 2026	William Blair	Steven Lichtman	Initiate	Outperform	—
Mar 31, 2026	Citigroup	Joanne Wuensch	Initiate	Buy	$23
Mar 31, 2026	Piper Sandler	Matt O'Brien	Initiate	Neutral	$16
Mar 31, 2026	Mizuho	Anthony Petrone	Initiate	Outperform	$21
Mar 31, 2026	Wells Fargo	Larry Biegelsen	Initiate	Overweight	$26
Mar 31, 2026	Morgan Stanley	Kallum Titchmarsh	Initiate	Overweight	$19
Mar 31, 2026	Evercore ISI Group	Daniel Markowitz	Initiate	Outperform	$20

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21

Morgan Stanley analyst Kallum Titchmarsh maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $19 to $21.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Minimed Group, Raises Price Target to $26

Citigroup analyst Joanne Wuensch maintains Minimed Group (NASDAQ:MMED) with a Buy and raises the price target from $23 to $26.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Minimed Group, Raises Price Target to $27

Evercore ISI Group analyst Daniel Markowitz maintains Minimed Group (NASDAQ:MMED) with a Outperform and raises the price target from $20 to $27.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Minimed Group, Raises Price Target to $26

Wells Fargo analyst Larry Biegelsen maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $22 to $26.

Benzinga Newsdesk

These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results

MiniMed Group beat Q1 sales estimates with 16.6% growth to $843M; shares rose 7.1% as analysts raised price targets to $26-$28.

Avi Kapoor

PRO
UBS Maintains Buy on Minimed Group, Raises Price Target to $28

UBS analyst Patrick Wood maintains Minimed Group (NASDAQ:MMED) with a Buy and raises the price target from $25 to $28.

Benzinga Newsdesk

Minimed Group Inc

Minimed Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21

PRO
Citigroup Maintains Buy on Minimed Group, Raises Price Target to $26

PRO
Evercore ISI Group Maintains Outperform on Minimed Group, Raises Price Target to $27

PRO
Wells Fargo Maintains Overweight on Minimed Group, Raises Price Target to $26

These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results

PRO
UBS Maintains Buy on Minimed Group, Raises Price Target to $28

People Also Watch

People Also Watch

Minimed Group Inc

Minimed Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21

PROCitigroup Maintains Buy on Minimed Group, Raises Price Target to $26

PROEvercore ISI Group Maintains Outperform on Minimed Group, Raises Price Target to $27

PROWells Fargo Maintains Overweight on Minimed Group, Raises Price Target to $26

These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results

PROUBS Maintains Buy on Minimed Group, Raises Price Target to $28

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21

PRO
Citigroup Maintains Buy on Minimed Group, Raises Price Target to $26

PRO
Evercore ISI Group Maintains Outperform on Minimed Group, Raises Price Target to $27

PRO
Wells Fargo Maintains Overweight on Minimed Group, Raises Price Target to $26

PRO
UBS Maintains Buy on Minimed Group, Raises Price Target to $28